AC
ACAD icon

AXQ Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

AXQ Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-19,680
Closed -$320K – 416
2024
Q2 		$320K Buy
19,680
+2,901
+17% +$46.8K 0.07% 358
2024
Q1 		$310K Buy
16,779
+8,278
+97% +$205K 0.07% 422
2023
Q4 		$266K Sell
8,501
-11,050
-57% -$264K 0.07% 416
2023
Q3 		$407K Buy
+19,551
New +$531K 0.14% 242
2023
Q2 		– Sell
-12,339
Closed -$232K – 264
2023
Q1 		$232K Buy
+12,339
New +$235K 0.09% 372

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return